<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070302</url>
  </required_header>
  <id_info>
    <org_study_id>85700</org_study_id>
    <secondary_id>85700</secondary_id>
    <nct_id>NCT02070302</nct_id>
  </id_info>
  <brief_title>BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome</brief_title>
  <official_title>BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benjamin Sucher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arizona Arthritis &amp; Rheumatology Research, PLLC.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective double blind controlled randomized trial of ten patients
      diagnosed with Carpal Tunnel Syndrome (CTS). The study will be completed at offices of
      medical practices in Arizona. Patients who meet inclusion criteria will be randomly
      distributed into two groups: a BOTOX® (onabotulinumtoxin A) injection group and a Normal
      Saline Injection (NS) (Placebo group). Each group will consist of five randomly assigned
      individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study, to assist with determining appropriate BOTOX® (onabotulinumtoxin A)
      dosing and injection locations in patients suffering from CTS.

      Outcome measures will be obtained at follow-up at 6, 12, and 18 weeks post BOTOX®
      (onabotulinumtoxin A) injection and post saline injection using the same scales and
      instruments at baseline, namely Levine scale, JAMAR pinch dynamometer, EDX/NCS and NMUS.
      These measurements will be used to identify the effectiveness of BOTOX® (onabotulinumtoxin A)
      in decreasing thenar muscle strength, appropriate BOTOX® (onabotulinumtoxin A) injection
      dosing, and ability to decrease the inflammation, median nerve dysfunction, edema, symptoms
      of pain, numbness, and tingling often with associated with CTS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Levine Symptom Severity Scale Status at Weeks 6, 12,18.</measure>
    <time_frame>Baseline-Week 18</time_frame>
    <description>Patients with Levine score &lt; 4 were included in the study. The score for this assessment can range from 11-55.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Levine Function Severity Scale Status at Weeks 6, 12,18.</measure>
    <time_frame>Baseline-Week 18</time_frame>
    <description>Patients with Levine score of &lt; 4 were included in the study. The score for this assessment can range from 8-40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Median Nerve Compression on Neuromuscular Ultrasound at Week 6, Week 12, and Week 18.</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>Neuromuscular ultrasound measures nerve compression (swelling) by cross sectional area of median nerve, in format % change from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Electrodiagnostics Distal Sensory Median Nerve Latency at Week 6, Week 12, and Week 18.</measure>
    <time_frame>Baseline, week 6, week 12, and week 18.</time_frame>
    <description>Latency is the interval between the stimulation of a muscle and the observed response, measuring conduction speed in milliseconds compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Electrodiagnostics Motor Median Nerve Latency at Week 6, Week 12, and Week 18.</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>Latency is the interval between the stimulation of a muscle and the observed response measuring nerve conduction speed in milliseconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Jamar Pinch (Unrelated Dominant Hand - Mean Value of All Repetitions/Positions) at Weeks 6, 12,18.</measure>
    <time_frame>Baseline-Week 18</time_frame>
    <description>Mean value of one finger and two finger opposition pinch between 1st and 5th and 1st with 4th and 5th phalanges.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each</description>
    <arm_group_label>Botulinum Toxin Type A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient history: evaluated using the Levine Scale for CTS, a self-administered
             questionnaire which assesses the function and severity of CTS.

          -  Physical Exam: including use of JAMAR pinch dynamometer to quantify initial baseline
             strength and confirm decreased pinch strength post injection to verify effective
             BOTOX® (onabotulinumtoxin A) injection.

          -  Electrodiagnostics (EDX): The following criteria would establish CTS through EDX
             namely baseline electromyogram (EMG) and nerve conduction studies (NCS): a) median
             nerve distal motor latency (DML) &gt;4.3ms or &gt;0.9ms above the ulnar nerve DML b) median
             distal sensory latency (DSL) to D-1 &gt;2.9ms or &gt;0.4ms above radial nerve D-1 DSL. c)
             median D-2 DSL &gt;3.7ms or &gt;0.4ms above ulnar nerve D-5 DSL (5). d) median mixed nerve
             palm-to-wrist latency (at 8cm) &gt;2.2ms or &gt;.3ms above ulnar mixed nerve palm-to-wrist
             latency (at 8cm).

          -  Imaging &amp; Measurements (NMUS): Carpal tunnel images will be obtained in a transverse
             plane in both a neutral relaxed position at the level of the pisiform and
             longitudinally during neutral and Dynamic Stress Testing (DST) by a A Sonosite M-Turbo
             6-13 MHz ultrasound system or another similar system (+ 2% accuracy). Measurements:
             Transverse images of the CT will measure the median nerve cross sectional area (CSA)
             at the level of the pisiform bone. CSA measurements greater than 11 mm2 are indicative
             of CTS. Borderline CSA measurements would require wrist forearm ratio (WFR)
             measurements to be a WFR &gt; 1.5. Patients will need to have a CSA &gt;11mm2, (or WFR &gt;1.5)
             and show median nerve compression during DST of at least 30% to be included.

        Exclusion Criteria:

          -  Patients with prior carpal tunnel surgery, prior history of BOTOX® (onabotulinumtoxin
             A) injection

          -  Steroid injection two months prior or three months after BOTOX® (onabotulinumtoxin A)
             CTS injection, median nerve denervation on needle EMG

          -  Major limb trauma or surgery, dysphagia

          -  Neuromuscular junction disorder (ie: Myasthenia gravis or Lambert-Eaton syndrome)

          -  Currently pregnant or breast feeding

          -  Patients with severe CTS identified by Levine scale &gt;4, electrodiagnostics, and/or
             unable to meet the inclusion criteria as identified above would be excluded as
             participants in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Sucher, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Arthritis &amp; Rheumatology Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>September 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2017</results_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Arizona Arthritis &amp; Rheumatology Research, PLLC.</investigator_affiliation>
    <investigator_full_name>Benjamin Sucher</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Botulinum Toxin Type A</title>
          <description>After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Botulinum Toxin Type A: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Placebo: Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>10 patients with bilateral CTS, diagnosed by nerve conduction studies and NMUS (with crosssectional area measurements; and percentage of nerve compression measured during mechanical stress testing), divided into control and Onabot groups. Non-dominant hands were injected under ultrasound guidance with 40 units (0.4 cc) of Onabot or normal saline.</population>
      <group_list>
        <group group_id="B1">
          <title>Botulinum Toxin Type A (Onabot)</title>
          <description>A prospective, randomized, double blind pilot study of patients with bilateral mild to moderate CTS, diagnosed by nerve conduction studies (NCS) and NMUS (with crosssectional area measurements; and percentage of nerve compression measured during mechanical stress testing). For 5 out of 10 subjects, non-dominant hands were injected under ultrasound guidance with 40 units of Onabot (0.4cc) divided equally into the abductor pollicis brevis and opponens pollicis muscles. Participants were evaluated with NMUS, NCS, Levine Scale (symptom severity and functional status), and Jamar dynamometer at baseline, 6, 12, and 18 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A prospective, randomized, double blind pilot study of 10 patients with bilateral mild to moderate CTS, diagnosed by nerve conduction studies (NCS) and NMUS (with crosssectional area measurements; and percentage of nerve compression measured during mechanical stress testing). Non-dominant hands were injected under ultrasound guidance with 40 units of 40 units of normal saline (0.4cc) divided equally into the abductor pollicis brevis and opponens pollicis muscles. Participants were evaluated with NMUS, NCS, Levine Scale (symptom severity and functional status), and Jamar dynamometer at baseline, 6, 12, and 18 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="17.9"/>
                    <measurement group_id="B2" value="52.3" spread="20.3"/>
                    <measurement group_id="B3" value="56.35" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Levine Symptom Severity Scale Status at Weeks 6, 12,18.</title>
        <description>Patients with Levine score &lt; 4 were included in the study. The score for this assessment can range from 11-55.</description>
        <time_frame>Baseline-Week 18</time_frame>
        <population>Levine symptom severity scale is a measure of mean of median value calculated for both Onabot and Placebo groups based on patient answered questions. It ranges from 1 (no symptoms) to 5 (severe symptoms). This scale indicate how severe the CTS symptoms feel to the patient. Mean values (std deviation) are reported both Onabot and Placebo groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A</title>
            <description>After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Botulinum Toxin Type A: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Placebo: Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Levine Symptom Severity Scale Status at Weeks 6, 12,18.</title>
          <description>Patients with Levine score &lt; 4 were included in the study. The score for this assessment can range from 11-55.</description>
          <population>Levine symptom severity scale is a measure of mean of median value calculated for both Onabot and Placebo groups based on patient answered questions. It ranges from 1 (no symptoms) to 5 (severe symptoms). This scale indicate how severe the CTS symptoms feel to the patient. Mean values (std deviation) are reported both Onabot and Placebo groups.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2-Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="6.8"/>
                    <measurement group_id="O2" value="-3.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3-Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="5.1"/>
                    <measurement group_id="O2" value="-9.4" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4-Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="8.7"/>
                    <measurement group_id="O2" value="-6.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Levine Function Severity Scale Status at Weeks 6, 12,18.</title>
        <description>Patients with Levine score of &lt; 4 were included in the study. The score for this assessment can range from 8-40</description>
        <time_frame>Baseline-Week 18</time_frame>
        <population>Levine functional severity scale is a measure of mean of median value calculated for both Onabot and Placebo groups based on patient answered questions. This scale ranges from 1 (no symptoms) to 5 (severe symptoms). The function severity scale indicate interference of the symptoms on activities of daily living. Mean values reported for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A</title>
            <description>After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Botulinum Toxin Type A: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Placebo: Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Levine Function Severity Scale Status at Weeks 6, 12,18.</title>
          <description>Patients with Levine score of &lt; 4 were included in the study. The score for this assessment can range from 8-40</description>
          <population>Levine functional severity scale is a measure of mean of median value calculated for both Onabot and Placebo groups based on patient answered questions. This scale ranges from 1 (no symptoms) to 5 (severe symptoms). The function severity scale indicate interference of the symptoms on activities of daily living. Mean values reported for each group.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2-Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="9.3"/>
                    <measurement group_id="O2" value="-4.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3-Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="4.8"/>
                    <measurement group_id="O2" value="-9.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4-Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="8.6"/>
                    <measurement group_id="O2" value="-12.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Median Nerve Compression on Neuromuscular Ultrasound at Week 6, Week 12, and Week 18.</title>
        <description>Neuromuscular ultrasound measures nerve compression (swelling) by cross sectional area of median nerve, in format % change from baseline.</description>
        <time_frame>Baseline to Week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A</title>
            <description>After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Botulinum Toxin Type A: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Placebo: Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Median Nerve Compression on Neuromuscular Ultrasound at Week 6, Week 12, and Week 18.</title>
          <description>Neuromuscular ultrasound measures nerve compression (swelling) by cross sectional area of median nerve, in format % change from baseline.</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2-Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="15.3"/>
                    <measurement group_id="O2" value="-20.2" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3-Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="19.5"/>
                    <measurement group_id="O2" value="-13.3" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4-Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="17.8"/>
                    <measurement group_id="O2" value="-4.7" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Electrodiagnostics Distal Sensory Median Nerve Latency at Week 6, Week 12, and Week 18.</title>
        <description>Latency is the interval between the stimulation of a muscle and the observed response, measuring conduction speed in milliseconds compared to baseline</description>
        <time_frame>Baseline, week 6, week 12, and week 18.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A</title>
            <description>After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Botulinum Toxin Type A: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Placebo: Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Electrodiagnostics Distal Sensory Median Nerve Latency at Week 6, Week 12, and Week 18.</title>
          <description>Latency is the interval between the stimulation of a muscle and the observed response, measuring conduction speed in milliseconds compared to baseline</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2-Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.4"/>
                    <measurement group_id="O2" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3-Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4-Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Electrodiagnostics Motor Median Nerve Latency at Week 6, Week 12, and Week 18.</title>
        <description>Latency is the interval between the stimulation of a muscle and the observed response measuring nerve conduction speed in milliseconds.</description>
        <time_frame>Baseline to Week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A</title>
            <description>After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Botulinum Toxin Type A: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Placebo: Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Electrodiagnostics Motor Median Nerve Latency at Week 6, Week 12, and Week 18.</title>
          <description>Latency is the interval between the stimulation of a muscle and the observed response measuring nerve conduction speed in milliseconds.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2-Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3-Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4-Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Jamar Pinch (Unrelated Dominant Hand - Mean Value of All Repetitions/Positions) at Weeks 6, 12,18.</title>
        <description>Mean value of one finger and two finger opposition pinch between 1st and 5th and 1st with 4th and 5th phalanges.</description>
        <time_frame>Baseline-Week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A</title>
            <description>After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Botulinum Toxin Type A: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Placebo: Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Jamar Pinch (Unrelated Dominant Hand - Mean Value of All Repetitions/Positions) at Weeks 6, 12,18.</title>
          <description>Mean value of one finger and two finger opposition pinch between 1st and 5th and 1st with 4th and 5th phalanges.</description>
          <units>Pounds of Force (LBF)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2-Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.2"/>
                    <measurement group_id="O2" value="0.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3-Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4-Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.5"/>
                    <measurement group_id="O2" value="0.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Botulinum Toxin Type A</title>
          <description>At 18 weeks, mean distal motor latency changes of -0.6 ms (P-value = 0.078) in the Onabot group were noted; and distal sensory latency changes of -0.3ms in the Onabot group; less slowing. Decreased mean cross-sectional area of -2.2 mm2 (P-value =0.040) in Onabot group were noted; less nerve edema. Decreased percent compression of the median nerve during stress testing was -12.6% in Onabot group. Three subjects injected with Onabot demonstrated decreases in median distal motor latencies that were nearly significant (p-value&lt;.1, &gt;.05), Two had decreases in median distal sensory latencies, and some had decreases in cross-sectional area on NMUS that were nearly significant. One Onabot subject did not show improvement or changes in median distal latencies but remained stable while the non-injected hand worsened with increasing median distal latencies.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
Placebo: Placebo (Normal Saline) divided into 2 injections of .4cc each</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Left Neck Pain</sub_title>
                <description>Unrelated to the study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neck Stiffness</sub_title>
                <description>Unrelated to the study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Right Hand Weakness</sub_title>
                <description>Related to the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash on Left Groin Area. Not related to the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amanda Santimaw</name_or_title>
      <organization>Arizona Arthritis &amp; Rheumatology Research, PLLC</organization>
      <phone>4806266653</phone>
      <email>amanda.santimaw@azarthritis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

